Switching from Warfarin to rivaroxaban induces sufficiency of vitamin K and reduction of arterial stiffness in patients with atrial fibrillation View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-06-23

AUTHORS

Yuji Ikari, Fumie Saito, Takahiko Kiyooka, Masakazu Nagaoka, Manabu Kimura, Takayuki Furuki, Shigemitsu Tanaka

ABSTRACT

Use of chronic vitamin K antagonist (VKA) induces a long-term deficiency of vitamin K, which may cause arterial stiffness and bone-related disease. Switching from VKA to rivaroxaban could induce rapid sufficiency of vitamin K and improvement of arterial stiffness. The K2 SUMMIT-3 study is a multicenter, open-label, prospective, and randomized design. Patients with atrial fibrillation who have been taking VKA for more than 6 months but less than 10 years were randomly assigned to two groups; those switching from VKA to rivaroxaban and those continuing with VKA medication. The primary endpoint was the percentage difference of brachial-ankle pulse wave velocity (baPWV) in 3 months. A total of 77 patients were randomly assigned to receive rivaroxaban (n = 38) or VKA (n = 39). The average age was 74 ± 9 years. The duration for which VKA was prescribed prior to randomization was 90 ± 87 months.Abnormally high levels of Des-gamma carboxyprothrombin (PIVKA-II) or uncarboxylated osteocalcin (ucOC) indicating vitamin K insufficiency were observed in 100% or 82% of the patients at baseline but it reduced to 2% (p < 0.0001) or 55% (p = 0.01) at 3 months in the rivaroxaban group. To the contrary, theses data had no changes in the VKA group. The percentage difference in baPWV was − 1.4 ± 10.0% vs. 3.5 ± 14.7% in the rivaroxaban and the VKA groups, respectively. (p = 0.02). Switching from VKA to rivaroxaban resulted in rapid sufficiency of vitamin K and reduction of arterial stiffness in 3 months. More... »

PAGES

1727-1733

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00380-020-01651-8

DOI

http://dx.doi.org/10.1007/s00380-020-01651-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1128714952

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32577819


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Fibrillation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Substitution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Factor Xa Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rivaroxaban", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Stiffness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vitamin K Deficiency", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Warfarin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, 259-1193, Isehara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265061.6", 
          "name": [
            "Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, 259-1193, Isehara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ikari", 
        "givenName": "Yuji", 
        "id": "sg:person.01230000060.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230000060.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, 259-1193, Isehara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.265061.6", 
          "name": [
            "Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, 259-1193, Isehara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saito", 
        "givenName": "Fumie", 
        "id": "sg:person.010202254301.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010202254301.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tokai University Oiso Hospital, Oiso, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412768.e", 
          "name": [
            "Tokai University Oiso Hospital, Oiso, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kiyooka", 
        "givenName": "Takahiko", 
        "id": "sg:person.01364071734.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364071734.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ebina General Hospital, Ebina, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459497.2", 
          "name": [
            "Ebina General Hospital, Ebina, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagaoka", 
        "givenName": "Masakazu", 
        "id": "sg:person.01050714447.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050714447.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tokai University Tokyo Hospital, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Tokai University Tokyo Hospital, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kimura", 
        "givenName": "Manabu", 
        "id": "sg:person.015000506651.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015000506651.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hadano South Gate Clinic, Hadano, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Hadano South Gate Clinic, Hadano, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furuki", 
        "givenName": "Takayuki", 
        "id": "sg:person.013755155767.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013755155767.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tokai University Oiso Hospital, Oiso, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412768.e", 
          "name": [
            "Tokai University Oiso Hospital, Oiso, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Shigemitsu", 
        "id": "sg:person.01237701721.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237701721.96"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00380-017-0950-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083862484", 
          "https://doi.org/10.1007/s00380-017-0950-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00394-019-01998-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1115170765", 
          "https://doi.org/10.1007/s00394-019-01998-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12937-016-0175-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035001632", 
          "https://doi.org/10.1186/s12937-016-0175-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/hr.2015.8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037859200", 
          "https://doi.org/10.1038/hr.2015.8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/jhh.2015.55", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002680833", 
          "https://doi.org/10.1038/jhh.2015.55"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-06-23", 
    "datePublishedReg": "2020-06-23", 
    "description": "Use of chronic vitamin K antagonist (VKA) induces a long-term deficiency of vitamin K, which may cause arterial stiffness and bone-related disease. Switching from VKA to rivaroxaban could induce rapid sufficiency of vitamin K and improvement of arterial stiffness. The K2 SUMMIT-3 study is a multicenter, open-label, prospective, and randomized design. Patients with atrial fibrillation who have been taking VKA for more than 6\u00a0months but less than 10\u00a0years were randomly assigned to two groups; those switching from VKA to rivaroxaban and those continuing with VKA medication. The primary endpoint was the percentage difference of brachial-ankle pulse wave velocity (baPWV) in 3\u00a0months. A total of 77 patients were randomly assigned to receive rivaroxaban (n\u2009=\u200938) or VKA (n\u2009=\u200939). The average age was 74\u2009\u00b1\u20099\u00a0years. The duration for which VKA was prescribed prior to randomization was 90\u2009\u00b1\u200987\u00a0months.Abnormally high levels of Des-gamma carboxyprothrombin (PIVKA-II) or uncarboxylated osteocalcin (ucOC) indicating vitamin K insufficiency were observed in 100% or 82% of the patients at baseline but it reduced to 2% (p\u2009<\u20090.0001) or 55% (p\u2009=\u20090.01) at 3\u00a0months in the rivaroxaban group. To the contrary, theses data had no changes in the VKA group. The percentage difference in baPWV was\u2009\u2212\u20091.4\u2009\u00b1\u200910.0% vs. 3.5\u2009\u00b1\u200914.7% in the rivaroxaban and the VKA groups, respectively. (p\u2009=\u20090.02). Switching from VKA to rivaroxaban resulted in rapid sufficiency of vitamin K and reduction of arterial stiffness in 3\u00a0months.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00380-020-01651-8", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1095887", 
        "issn": [
          "0910-8327", 
          "1615-2573"
        ], 
        "name": "Heart and Vessels", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "keywords": [
      "brachial-ankle pulse wave velocity", 
      "vitamin K antagonists", 
      "arterial stiffness", 
      "vitamin K", 
      "VKA group", 
      "atrial fibrillation", 
      "des-gamma carboxyprothrombin", 
      "vitamin K insufficiency", 
      "pulse wave velocity", 
      "VKA medication", 
      "rivaroxaban group", 
      "K antagonists", 
      "long-term deficiency", 
      "primary endpoint", 
      "rivaroxaban", 
      "bone-related diseases", 
      "average age", 
      "patients", 
      "months", 
      "percentage difference", 
      "fibrillation", 
      "group", 
      "multicenter", 
      "high levels", 
      "medications", 
      "carboxyprothrombin", 
      "randomized design", 
      "warfarin", 
      "antagonist", 
      "insufficiency", 
      "years", 
      "wave velocity", 
      "disease", 
      "baseline", 
      "endpoint", 
      "age", 
      "osteocalcin", 
      "differences", 
      "total", 
      "randomization", 
      "duration", 
      "deficiency", 
      "reduction", 
      "sufficiency", 
      "levels", 
      "stiffness", 
      "study", 
      "improvement", 
      "changes", 
      "use", 
      "data", 
      "contrary", 
      "design", 
      "velocity"
    ], 
    "name": "Switching from Warfarin to rivaroxaban induces sufficiency of vitamin K and reduction of arterial stiffness in patients with atrial fibrillation", 
    "pagination": "1727-1733", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1128714952"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00380-020-01651-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32577819"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00380-020-01651-8", 
      "https://app.dimensions.ai/details/publication/pub.1128714952"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_876.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00380-020-01651-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00380-020-01651-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00380-020-01651-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00380-020-01651-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00380-020-01651-8'


 

This table displays all metadata directly associated to this object as RDF triples.

261 TRIPLES      21 PREDICATES      102 URIs      89 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00380-020-01651-8 schema:about N13752b03f20142d480419d8215a56e78
2 N1c39261a048e4940b257cad912c98e0f
3 N38dfb0cf866e4baa8de6330f6f56bb33
4 N3f090ce0ba314d7e865cb90345228511
5 N5ebe7eb8cbd74e6ba93e9a171e5b8c8b
6 N67f0d782a03844fa97063b3d3fb912f5
7 N687f999e9ab94d98a55c95e42b487c11
8 N6a9b6b9f120b4be5b6f4d010f2334246
9 N77c498c4c5fb44f8b4f12f02f17eaa48
10 N93ff9ebdc2214630a9d4afd43c5fb810
11 Na25c74347ca441b796b92cc0d4082fc9
12 Naf96485bb3974d2390d7fcd321b421bc
13 Nb5282db837e948189b18f62fa50aa6a2
14 Nb76275d1ff4542e9a89081b83815ee8c
15 Ncbd1cdfc0072488fa672b526c66fa3c1
16 Ncc2bbd42a8924dcc933faeeb7f1b88e5
17 Ne77e0c43fe0846aa85d6a7d62b059c6d
18 Nf393a9a0d33c439090d3fd29a12f6333
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author Nfb053d8f31714fe4be5492dd40724a05
22 schema:citation sg:pub.10.1007/s00380-017-0950-2
23 sg:pub.10.1007/s00394-019-01998-3
24 sg:pub.10.1038/hr.2015.8
25 sg:pub.10.1038/jhh.2015.55
26 sg:pub.10.1186/s12937-016-0175-8
27 schema:datePublished 2020-06-23
28 schema:datePublishedReg 2020-06-23
29 schema:description Use of chronic vitamin K antagonist (VKA) induces a long-term deficiency of vitamin K, which may cause arterial stiffness and bone-related disease. Switching from VKA to rivaroxaban could induce rapid sufficiency of vitamin K and improvement of arterial stiffness. The K2 SUMMIT-3 study is a multicenter, open-label, prospective, and randomized design. Patients with atrial fibrillation who have been taking VKA for more than 6 months but less than 10 years were randomly assigned to two groups; those switching from VKA to rivaroxaban and those continuing with VKA medication. The primary endpoint was the percentage difference of brachial-ankle pulse wave velocity (baPWV) in 3 months. A total of 77 patients were randomly assigned to receive rivaroxaban (n = 38) or VKA (n = 39). The average age was 74 ± 9 years. The duration for which VKA was prescribed prior to randomization was 90 ± 87 months.Abnormally high levels of Des-gamma carboxyprothrombin (PIVKA-II) or uncarboxylated osteocalcin (ucOC) indicating vitamin K insufficiency were observed in 100% or 82% of the patients at baseline but it reduced to 2% (p < 0.0001) or 55% (p = 0.01) at 3 months in the rivaroxaban group. To the contrary, theses data had no changes in the VKA group. The percentage difference in baPWV was − 1.4 ± 10.0% vs. 3.5 ± 14.7% in the rivaroxaban and the VKA groups, respectively. (p = 0.02). Switching from VKA to rivaroxaban resulted in rapid sufficiency of vitamin K and reduction of arterial stiffness in 3 months.
30 schema:genre article
31 schema:isAccessibleForFree false
32 schema:isPartOf Nbf6ca1fc9ab2438a993c65c9a199400e
33 Nd0e156ae848c4a26b220f5a7c570bb55
34 sg:journal.1095887
35 schema:keywords K antagonists
36 VKA group
37 VKA medication
38 age
39 antagonist
40 arterial stiffness
41 atrial fibrillation
42 average age
43 baseline
44 bone-related diseases
45 brachial-ankle pulse wave velocity
46 carboxyprothrombin
47 changes
48 contrary
49 data
50 deficiency
51 des-gamma carboxyprothrombin
52 design
53 differences
54 disease
55 duration
56 endpoint
57 fibrillation
58 group
59 high levels
60 improvement
61 insufficiency
62 levels
63 long-term deficiency
64 medications
65 months
66 multicenter
67 osteocalcin
68 patients
69 percentage difference
70 primary endpoint
71 pulse wave velocity
72 randomization
73 randomized design
74 reduction
75 rivaroxaban
76 rivaroxaban group
77 stiffness
78 study
79 sufficiency
80 total
81 use
82 velocity
83 vitamin K
84 vitamin K antagonists
85 vitamin K insufficiency
86 warfarin
87 wave velocity
88 years
89 schema:name Switching from Warfarin to rivaroxaban induces sufficiency of vitamin K and reduction of arterial stiffness in patients with atrial fibrillation
90 schema:pagination 1727-1733
91 schema:productId N368bca971d2641cab941514524c6a4d9
92 N4578dc546725480eb04f129db5af5f78
93 N59c743c3cafd49818e04e96d25223d77
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128714952
95 https://doi.org/10.1007/s00380-020-01651-8
96 schema:sdDatePublished 2022-10-01T06:48
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N231a23bb423d465987f5eb3bb03b791e
99 schema:url https://doi.org/10.1007/s00380-020-01651-8
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N13752b03f20142d480419d8215a56e78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Factor Xa Inhibitors
105 rdf:type schema:DefinedTerm
106 N1c39261a048e4940b257cad912c98e0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Humans
108 rdf:type schema:DefinedTerm
109 N231a23bb423d465987f5eb3bb03b791e schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 N368bca971d2641cab941514524c6a4d9 schema:name doi
112 schema:value 10.1007/s00380-020-01651-8
113 rdf:type schema:PropertyValue
114 N38dfb0cf866e4baa8de6330f6f56bb33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Treatment Outcome
116 rdf:type schema:DefinedTerm
117 N3f090ce0ba314d7e865cb90345228511 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Atrial Fibrillation
119 rdf:type schema:DefinedTerm
120 N4578dc546725480eb04f129db5af5f78 schema:name pubmed_id
121 schema:value 32577819
122 rdf:type schema:PropertyValue
123 N4a6d605271c54b7ba036462bc8828b82 rdf:first sg:person.01237701721.96
124 rdf:rest rdf:nil
125 N4be47641d52547e8aeaa42b64dd0d96d rdf:first sg:person.010202254301.72
126 rdf:rest Nbed41afe05e342f29a8e961434a22c4e
127 N59c743c3cafd49818e04e96d25223d77 schema:name dimensions_id
128 schema:value pub.1128714952
129 rdf:type schema:PropertyValue
130 N5ebe7eb8cbd74e6ba93e9a171e5b8c8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Vitamin K Deficiency
132 rdf:type schema:DefinedTerm
133 N67f0d782a03844fa97063b3d3fb912f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Aged, 80 and over
135 rdf:type schema:DefinedTerm
136 N687f999e9ab94d98a55c95e42b487c11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Rivaroxaban
138 rdf:type schema:DefinedTerm
139 N6a9b6b9f120b4be5b6f4d010f2334246 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Time Factors
141 rdf:type schema:DefinedTerm
142 N77c498c4c5fb44f8b4f12f02f17eaa48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Male
144 rdf:type schema:DefinedTerm
145 N93ff9ebdc2214630a9d4afd43c5fb810 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Japan
147 rdf:type schema:DefinedTerm
148 Na25c74347ca441b796b92cc0d4082fc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Prospective Studies
150 rdf:type schema:DefinedTerm
151 Naf96485bb3974d2390d7fcd321b421bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Female
153 rdf:type schema:DefinedTerm
154 Nb5282db837e948189b18f62fa50aa6a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Vascular Stiffness
156 rdf:type schema:DefinedTerm
157 Nb76275d1ff4542e9a89081b83815ee8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Drug Substitution
159 rdf:type schema:DefinedTerm
160 Nbed41afe05e342f29a8e961434a22c4e rdf:first sg:person.01364071734.77
161 rdf:rest Ncbd0a7fd5b164cddaf450d667a3aa27d
162 Nbf6ca1fc9ab2438a993c65c9a199400e schema:volumeNumber 35
163 rdf:type schema:PublicationVolume
164 Ncbd0a7fd5b164cddaf450d667a3aa27d rdf:first sg:person.01050714447.28
165 rdf:rest Nf3e00dd5800d48e7a5219da913cc8f4b
166 Ncbd1cdfc0072488fa672b526c66fa3c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Anticoagulants
168 rdf:type schema:DefinedTerm
169 Ncc2bbd42a8924dcc933faeeb7f1b88e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Warfarin
171 rdf:type schema:DefinedTerm
172 Nd0e156ae848c4a26b220f5a7c570bb55 schema:issueNumber 12
173 rdf:type schema:PublicationIssue
174 Ne77e0c43fe0846aa85d6a7d62b059c6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Aged
176 rdf:type schema:DefinedTerm
177 Nf393a9a0d33c439090d3fd29a12f6333 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Middle Aged
179 rdf:type schema:DefinedTerm
180 Nf3e00dd5800d48e7a5219da913cc8f4b rdf:first sg:person.015000506651.12
181 rdf:rest Nf9047c4bbebb406096881a32dead503e
182 Nf9047c4bbebb406096881a32dead503e rdf:first sg:person.013755155767.61
183 rdf:rest N4a6d605271c54b7ba036462bc8828b82
184 Nfb053d8f31714fe4be5492dd40724a05 rdf:first sg:person.01230000060.40
185 rdf:rest N4be47641d52547e8aeaa42b64dd0d96d
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
190 schema:name Clinical Sciences
191 rdf:type schema:DefinedTerm
192 sg:journal.1095887 schema:issn 0910-8327
193 1615-2573
194 schema:name Heart and Vessels
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.010202254301.72 schema:affiliation grid-institutes:grid.265061.6
198 schema:familyName Saito
199 schema:givenName Fumie
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010202254301.72
201 rdf:type schema:Person
202 sg:person.01050714447.28 schema:affiliation grid-institutes:grid.459497.2
203 schema:familyName Nagaoka
204 schema:givenName Masakazu
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050714447.28
206 rdf:type schema:Person
207 sg:person.01230000060.40 schema:affiliation grid-institutes:grid.265061.6
208 schema:familyName Ikari
209 schema:givenName Yuji
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230000060.40
211 rdf:type schema:Person
212 sg:person.01237701721.96 schema:affiliation grid-institutes:grid.412768.e
213 schema:familyName Tanaka
214 schema:givenName Shigemitsu
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237701721.96
216 rdf:type schema:Person
217 sg:person.01364071734.77 schema:affiliation grid-institutes:grid.412768.e
218 schema:familyName Kiyooka
219 schema:givenName Takahiko
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364071734.77
221 rdf:type schema:Person
222 sg:person.013755155767.61 schema:affiliation grid-institutes:None
223 schema:familyName Furuki
224 schema:givenName Takayuki
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013755155767.61
226 rdf:type schema:Person
227 sg:person.015000506651.12 schema:affiliation grid-institutes:grid.412708.8
228 schema:familyName Kimura
229 schema:givenName Manabu
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015000506651.12
231 rdf:type schema:Person
232 sg:pub.10.1007/s00380-017-0950-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083862484
233 https://doi.org/10.1007/s00380-017-0950-2
234 rdf:type schema:CreativeWork
235 sg:pub.10.1007/s00394-019-01998-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1115170765
236 https://doi.org/10.1007/s00394-019-01998-3
237 rdf:type schema:CreativeWork
238 sg:pub.10.1038/hr.2015.8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037859200
239 https://doi.org/10.1038/hr.2015.8
240 rdf:type schema:CreativeWork
241 sg:pub.10.1038/jhh.2015.55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002680833
242 https://doi.org/10.1038/jhh.2015.55
243 rdf:type schema:CreativeWork
244 sg:pub.10.1186/s12937-016-0175-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035001632
245 https://doi.org/10.1186/s12937-016-0175-8
246 rdf:type schema:CreativeWork
247 grid-institutes:None schema:alternateName Hadano South Gate Clinic, Hadano, Japan
248 schema:name Hadano South Gate Clinic, Hadano, Japan
249 rdf:type schema:Organization
250 grid-institutes:grid.265061.6 schema:alternateName Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, 259-1193, Isehara, Japan
251 schema:name Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, 259-1193, Isehara, Japan
252 rdf:type schema:Organization
253 grid-institutes:grid.412708.8 schema:alternateName Tokai University Tokyo Hospital, Tokyo, Japan
254 schema:name Tokai University Tokyo Hospital, Tokyo, Japan
255 rdf:type schema:Organization
256 grid-institutes:grid.412768.e schema:alternateName Tokai University Oiso Hospital, Oiso, Japan
257 schema:name Tokai University Oiso Hospital, Oiso, Japan
258 rdf:type schema:Organization
259 grid-institutes:grid.459497.2 schema:alternateName Ebina General Hospital, Ebina, Japan
260 schema:name Ebina General Hospital, Ebina, Japan
261 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...